European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Single Molecule Imaging-based design of HIV-1 vaccines

Descrizione del progetto

Imaging dell’ingresso dell’HIV nelle cellule per favorire la progettazione del vaccino

La recente scoperta di anticorpi neutralizzanti contro l’HIV-1 ha riacceso i tentativi di realizzare un vaccino. Per aiutare la progettazione razionale del vaccino, gli scienziati del progetto FUSION, finanziato dall’UE, mirano a comprendere il meccanismo alla base del riconoscimento del target e caratterizzare le risposte anticorpali policlonali. A tal fine, impiegheranno tecniche di imaging a risoluzione temporale all’avanguardia per visualizzare la fusione dell’HIV-1 sulla superficie delle cellule viventi e decifrare il meccanismo mediante il quale diversi anticorpi neutralizzanti interrompono questa fusione, che viene conservata tra i diversi ceppi di HIV. Svelando le principali interazioni tra cellule ospite e virus a livello molecolare, FUSION aprirà la strada alla progettazione di nuovi farmaci e vaccini.

Obiettivo

The HIV-1 vaccine research has re-emerged in the last few years due to the identification of antibodies that neutralize most HIV-1 circulating strains. A deeper understanding of the mechanistic mode of target recognition for these antibodies represents a big hope in the field. This project aims at understanding and characterizing polyclonal antibody responses to aid rational vaccine design via radically new technologies on light microscopy. The molecular mechanism of time-resolved HIV-1 fusion will be visualized and quantified on the surface of living cells by combining real-time single virus tracking, fluorescence fluctuation spectroscopy and 3D single molecule localization microscopy (SMLM) imaging. The implementation of a new technology that allows three-dimensional nanometre localization of single particles will allow us to multiplex single molecule experiments with functional readouts for single-virus HIV-1 fusion simultaneously. Here, I will systematically establish the mechanism of action of different families of neutralizing antibodies and how they disrupt the three-step HIV fusion reaction, conserved among different HIV tropism, recently discovered by our group. I will unveil the molecular insights on the precise Env-induced, time-resolved stoichiometry of CD4 and co-receptors (CCR5 or CXCR4) in the presence and absence of different combinations of bNAbs and study their impact on HIV transmission. FUSION will open new avenues to design putative drugs that target host-specific receptor and co-receptor oligomeric states to block HIV-1 fusion. This project systematically applies cutting-edge time-resolved imaging approaches as a gold standard to ascertain how different combinations of bNAbs perturb the HIV fusion mechanism in CD4+ T cells and macrophages. I will establish a world-class laboratory in HIV-1 and single molecule microscopy. I will decipher several key virus–host cell interactions at molecular level and contribute to rational vaccine and drug desig

Meccanismo di finanziamento

ERC-COG - Consolidator Grant

Istituzione ospitante

KING'S COLLEGE LONDON
Contribution nette de l'UE
€ 2 280 390,00
Indirizzo
STRAND
WC2R 2LS London
Regno Unito

Mostra sulla mappa

Regione
London Inner London — West Westminster
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 280 390,00

Beneficiari (1)